xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT06008912</url>
    </required_header>
    <id_info>
      <org_study_id>KA-22027</org_study_id>
      <nct_id>NCT06008912</nct_id>
    </id_info>
    <brief_title>Effect of Calisthenic Exercise Training Combined With Aerobic Exercise in Patients With Dyslipidemia</brief_title>
    <official_title>Investigation of the Effect of Calisthenic Exercise Training Combined With Aerobic Exercise on Exercise Tolerance, Physical Fitness and Plasma Lipid Profile in Patients With Dyslipidemia</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Çankırı Karatekin University</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
      <collaborator>
        <agency>Hacettepe University</agency>
        <agency_class>Other</agency_class>
      </collaborator>
    </sponsors>
    <source>Çankırı Karatekin University</source>
    <oversight_info>
      <has_dmc>No</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        Dyslipidemia is expressed as the serum concentration of lipid molecules with different&#xD;
        structures outside the normal level. Deviation of serum lipid level from normal is accepted&#xD;
        as the primary or most important factor in various cardiac and metabolic diseases, especially&#xD;
        atherosclerosis. Dyslipidemia-related cardiovascular structure change is accepted as an&#xD;
        important public health problem worldwide, and it is stated that the combined use of medical&#xD;
        treatment, changes in diet and physical activity/structured exercise programs in the&#xD;
        treatment of dyslipidemia is important in the success of treatment.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        Lipid profile disorders (especially high total blood cholesterol level) are a major problem&#xD;
        worldwide, and accepted as a important public health problem. It has been reported that&#xD;
        approximately one out of every three people worldwide has been exposed to dyslipidemia risk&#xD;
        factors. Prevalence studies showed that lipid profile disorders vary between 6.9% and 43.6%&#xD;
        worldwide. Today, ischemic heart and central nervous system diseases are the most important&#xD;
        causes of mortality and morbidity in adult population, globally. Especially, it is accepted&#xD;
        that lipid profile disorders are the leading risk factors causing ischemic heart diseases.&#xD;
  &#xD;
        Prevalence varies according to regions, lifestyle habits and individual factors, because of&#xD;
        lipid profile disorders are caused by many different genetic and environmental factors. Apart&#xD;
        from individual factors, there are other factors that lipid weight in diet, nutrient&#xD;
        deficiencies which balancing lipid metabolism, physical activity level and inactivity, other&#xD;
        comorbid diseases, and medical treatments change lipid metabolism in individuals and lead to&#xD;
        deterioration in lipid profile. Especially lifestyle habits affect lipid metabolism most&#xD;
        easily and they are the most easily modifiable factors.&#xD;
  &#xD;
        It is recommended to apply a multi-dimensional approach when treating lipid profile&#xD;
        disorders. It is recommended that, to include diet counseling and exercise therapy in these&#xD;
        approaches. Exercise therapy is especially recognized as an important treatment option for&#xD;
        the control and treatment of obesity, hypertension, hyperglycemia and metabolic syndrome&#xD;
        symptoms that may accompany dyslipidemia.&#xD;
  &#xD;
        It has been reported that aerobic exercise programs increase patients' quality of life and&#xD;
        functionality which applied to dyslipidemia patients, but there is lack of information&#xD;
        available in literature about the effects of calisthenic exercises in patients with&#xD;
        dyslipidemia.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">August 14, 2023</start_date>
    <completion_date type="Anticipated">January 31, 2025</completion_date>
    <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
    <phase>N/A</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>Randomized</allocation>
      <intervention_model>Parallel Assignment</intervention_model>
      <intervention_model_description>Experimental model of study consist from three arm.&#xD;
  First Arm: Patients will take aerobic exercise training in 3 days per week, and 7 days per week calisthenic exercises for upper extremity, lower extremity and trunk, for 8 weeks.&#xD;
  Second Arm: Patients will take aerobic exercise training in 3 days per week, for 8 weeks.&#xD;
  Third Arm: Patients will take physical activity recommendations, and just screening after 8 weeks.</intervention_model_description>
      <primary_purpose>Treatment</primary_purpose>
      <masking>Double (Participant, Care Provider)</masking>
      <masking_description>Patients and his/her caregivers will allocate in study via computer based randomisation, and will not know about his/her and also other participants group in study.</masking_description>
    </study_design_info>
    <primary_outcome>
      <measure>Exercise Capacity</measure>
      <time_frame>Second Day</time_frame>
      <description>Cardiopulmonary exercise capacity will assess as primary outcome measure, via cardiopulmonary exercise test (CPET).</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Blood Lipids Concentration Assessment</measure>
      <time_frame>First Day</time_frame>
      <description>Concentration of LDL-C, HDL-C, Total cholesterol (TC) and Triglyceride (TG) will assess in blood (in mg/dL units of measure) after 12 hours fasting.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Apolipoprotein A1 Concentration Assessment</measure>
      <time_frame>First Day</time_frame>
      <description>Concentration of Apolipoprotein A1 will assess in blood (in g/dL units of measure) after 12 hours fasting.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Blood Sugar Concentration Assessment</measure>
      <time_frame>First Day</time_frame>
      <description>Concentration of fasting blood sugar (in mmol/L units of measure) and rate of HbA1c (in % units of measure) will assess in blood after 12 hours fasting.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>C-reactive Protein Concentration Assessment</measure>
      <time_frame>First Day</time_frame>
      <description>Concentration of C-reactive protein (in mg/dL units of measure) will assess in blood after 12 hours fasting.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Sit-to-Stand Test</measure>
      <time_frame>First Day</time_frame>
      <description>A one-minute sit-to-stand test will be applied to the patients. One standing position followed by sitting will count as one cycle. Patients' total cycles within 60 seconds will be counted as test score (in cycle/minute units of measure)</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Timed Up-and-Go Test</measure>
      <time_frame>First Day</time_frame>
      <description>Timed up-and-go test will be applied to the patients. Patients will be asked to get up from the chair, walk the 3-meter distance, return and sit back in the chair, as quickly as possible. The total time that patients complete the test and sit on the chair again will be recorded as the test score (in second/lap units of measure).</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Peripheral Muscle Strength Assessment</measure>
      <time_frame>First Day</time_frame>
      <description>The muscle strength of the shoulder abductor and knee extensor muscles on the dominant and non-dominant sides of the patients will be evaluated with a portable dynamometer. During the evaluations, the patients will be asked to try to resist the force to be applied in the opposite direction of the relevant muscle's function with isometric muscle contraction. The force released during the test will be measured and the highest score (in newton [N] units of measure) will be recorded for each muscle within 3 tests.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Hand-Grip Strength Assessment</measure>
      <time_frame>First Day</time_frame>
      <description>The hand grip strength of the patients will be measured with a portable hand dynamometer. The patients will be asked to grasp the dynamometer with their fingers on the dominant and non-dominant side and squeeze it most strongly. The highest score (in kilogram force [KgF] units of measure) of 3 measurements on both sides will be recorded.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Flexibility Assessment</measure>
      <time_frame>First Day</time_frame>
      <description>Flexibility of patients will be evaluated with sit-and-reach test. Patients will be asked to stretch their hands on a bench with a measuring ruler while in a long sitting position with the ankle angled at 90 degrees and the knee fully extended. How many centimeters ahead or behind the toes of the patient's fingertips will be measured.</description>
    </secondary_outcome>
    <other_outcome>
      <measure>Quality of Life Assessment</measure>
      <time_frame>Second Day</time_frame>
      <description>Quality of life will assess via Short Form-36 Quality of Life Questionnaire. The questionnaire consist from 36 questions and total score ranges between 0 to 100 point. Higher scores shows better quality of life.</description>
    </other_outcome>
    <number_of_arms>3</number_of_arms>
    <enrollment type="Anticipated">24</enrollment>
    <condition>Dyslipidemias</condition>
    <arm_group>
      <arm_group_label>Calisthenic + Aerobic Exercise Group</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Patients will take aerobic exercise training in 3 days per week, and 7 days per week calisthenic exercises for upper extremity, lower extremity and trunk, for 8 weeks.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Aerobic Exercise Group</arm_group_label>
      <arm_group_type>Active Comparator</arm_group_type>
      <description>Patients will take aerobic exercise training in 3 days per week, for 8 weeks.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Control Group</arm_group_label>
      <arm_group_type>No Intervention</arm_group_type>
      <description>Patients will take physical activity recommendations, and just screening after 8 weeks.</description>
    </arm_group>
    <intervention>
      <intervention_type>Other</intervention_type>
      <intervention_name>Calisthenic Exercises</intervention_name>
      <description>Exercises for upper extremity, lower extremity and trunk which applying just patient's own body weight via using body mechanics. There is no need for any tools for exercises.</description>
      <arm_group_label>Calisthenic + Aerobic Exercise Group</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Other</intervention_type>
      <intervention_name>Aerobic Exercises</intervention_name>
      <description>Exercises which loading cardiovascular, respiratory and muscular system at the same time. Treadmill training will apply in the study.</description>
      <arm_group_label>Aerobic Exercise Group</arm_group_label>
      <arm_group_label>Calisthenic + Aerobic Exercise Group</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            -  Screening by the internal medicine clinic with the diagnosis of dyslipidemia&#xD;
  &#xD;
            -  Being between 18 to 65 years old&#xD;
  &#xD;
            -  Volunteering to participate in the research&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  Having any cardiac disease&#xD;
  &#xD;
            -  Having a co-existing psychiatric illness (like schizophrenia, bipolar disorder, etc.)&#xD;
  &#xD;
            -  Being infected with COVID-19 in the last 3 months&#xD;
  &#xD;
            -  Having any neurological problems that may affect cooperation&#xD;
  &#xD;
            -  Having pulmonary or orthopedic problem that may affect functional capacity&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>65 Years</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_contact>
      <last_name>Naciye Vardar-Yağlı, Prof. Dr.</last_name>
      <phone>+90-546-237-1990</phone>
      <email>naciyevardar@yahoo.com</email>
    </overall_contact>
    <location>
      <facility>
        <name>Hacettepe University</name>
        <address>
          <city>Ankara</city>
          <country>Turkey</country>
        </address>
      </facility>
    </location>
    <location_countries>
      <country>Turkey</country>
    </location_countries>
    <reference>
      <citation>GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016 Oct 8;388(10053):1659-1724. doi: 10.1016/S0140-6736(16)31679-8. Erratum In: Lancet. 2017 Jan 7;389(10064):e1.</citation>
      <PMID>27733284</PMID>
    </reference>
    <reference>
      <citation>Rivas-Gomez B, Almeda-Valdes P, Tussie-Luna MT, Aguilar-Salinas CA. DYSLIPIDEMIA IN MEXICO, A CALL FOR ACTION. Rev Invest Clin. 2018;70(5):211-216. doi: 10.24875/RIC.18002573.</citation>
      <PMID>30307444</PMID>
    </reference>
    <reference>
      <citation>Pan L, Yang Z, Wu Y, Yin RX, Liao Y, Wang J, Gao B, Zhang L; China National Survey of Chronic Kidney Disease Working Group. The prevalence, awareness, treatment and control of dyslipidemia among adults in China. Atherosclerosis. 2016 May;248:2-9. doi: 10.1016/j.atherosclerosis.2016.02.006. Epub 2016 Feb 27.</citation>
      <PMID>26978581</PMID>
    </reference>
    <reference>
      <citation>Zhang M, Deng Q, Wang L, Huang Z, Zhou M, Li Y, Zhao Z, Zhang Y, Wang L. Prevalence of dyslipidemia and achievement of low-density lipoprotein cholesterol targets in Chinese adults: A nationally representative survey of 163,641 adults. Int J Cardiol. 2018 Jun 1;260:196-203. doi: 10.1016/j.ijcard.2017.12.069. Erratum In: Int J Cardiol. 2018 May 12;:</citation>
      <PMID>29622441</PMID>
    </reference>
    <reference>
      <citation>Yang F, Ma Q, Ma B, Jing W, Liu J, Guo M, Li J, Wang Z, Liu M. Dyslipidemia prevalence and trends among adult mental disorder inpatients in Beijing, 2005-2018: A longitudinal observational study. Asian J Psychiatr. 2021 Mar;57:102583. doi: 10.1016/j.ajp.2021.102583. Epub 2021 Feb 5.</citation>
      <PMID>33581368</PMID>
    </reference>
    <reference>
      <citation>GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct 17;396(10258):1204-1222. doi: 10.1016/S0140-6736(20)30925-9. Erratum In: Lancet. 2020 Nov 14;396(10262):1562.</citation>
      <PMID>33069326</PMID>
    </reference>
    <reference>
      <citation>Tietge UJ. Hyperlipidemia and cardiovascular disease: inflammation, dyslipidemia, and atherosclerosis. Curr Opin Lipidol. 2014 Feb;25(1):94-5. doi: 10.1097/MOL.0000000000000051. No abstract available.</citation>
      <PMID>24398450</PMID>
    </reference>
    <reference>
      <citation>Villarreal-Molina MT, Aguilar-Salinas CA, Rodriguez-Cruz M, Riano D, Villalobos-Comparan M, Coral-Vazquez R, Menjivar M, Yescas-Gomez P, Konigsoerg-Fainstein M, Romero-Hidalgo S, Tusie-Luna MT, Canizales-Quinteros S; Metabolic Study Group. The ATP-binding cassette transporter A1 R230C variant affects HDL cholesterol levels and BMI in the Mexican population: association with obesity and obesity-related comorbidities. Diabetes. 2007 Jul;56(7):1881-7. doi: 10.2337/db06-0905. Epub 2007 Feb 7.</citation>
      <PMID>17287470</PMID>
    </reference>
    <reference>
      <citation>Villarreal-Molina MT, Flores-Dorantes MT, Arellano-Campos O, Villalobos-Comparan M, Rodriguez-Cruz M, Miliar-Garcia A, Huertas-Vazquez A, Menjivar M, Romero-Hidalgo S, Wacher NH, Tusie-Luna MT, Cruz M, Aguilar-Salinas CA, Canizales-Quinteros S; Metabolic Study Group. Association of the ATP-binding cassette transporter A1 R230C variant with early-onset type 2 diabetes in a Mexican population. Diabetes. 2008 Feb;57(2):509-13. doi: 10.2337/db07-0484. Epub 2007 Nov 14.</citation>
      <PMID>18003760</PMID>
    </reference>
    <reference>
      <citation>De Sousa SM Dr, Norman RJ Prof. Metabolic syndrome, diet and exercise. Best Pract Res Clin Obstet Gynaecol. 2016 Nov;37:140-151. doi: 10.1016/j.bpobgyn.2016.01.006. Epub 2016 Feb 10.</citation>
      <PMID>26972165</PMID>
    </reference>
    <reference>
      <citation>Wang Y, Xu D. Effects of aerobic exercise on lipids and lipoproteins. Lipids Health Dis. 2017 Jul 5;16(1):132. doi: 10.1186/s12944-017-0515-5.</citation>
      <PMID>28679436</PMID>
    </reference>
    <reference>
      <citation>Miles L. Physical activity and health. Nutr Bull [Internet]. 2007 Dec;32(4):314-63. Available from: http://doi.wiley.com/10.1111/j.1467-3010.2007.00668.x</citation>
    </reference>
    <reference>
      <citation>Strunk RC, Mrazek DA, Fukuhara JT, Masterson J, Ludwick SK, LaBrecque JF. Cardiovascular fitness in children with asthma correlates with psychologic functioning of the child. Pediatrics. 1989 Sep;84(3):460-4.</citation>
      <PMID>2771549</PMID>
    </reference>
    <reference>
      <citation>Carson KV, Chandratilleke MG, Picot J, Brinn MP, Esterman AJ, Smith BJ. Physical training for asthma. Cochrane Database Syst Rev. 2013 Sep 30;(9):CD001116. doi: 10.1002/14651858.CD001116.pub4.</citation>
      <PMID>24085631</PMID>
    </reference>
    <reference>
      <citation>Eime RM, Young JA, Harvey JT, Charity MJ, Payne WR. A systematic review of the psychological and social benefits of participation in sport for children and adolescents: informing development of a conceptual model of health through sport. Int J Behav Nutr Phys Act. 2013 Aug 15;10:98. doi: 10.1186/1479-5868-10-98.</citation>
      <PMID>23945179</PMID>
    </reference>
    <verification_date>August 2023</verification_date>
    <study_first_submitted>August 8, 2023</study_first_submitted>
    <study_first_submitted_qc>August 23, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 24, 2023</study_first_posted>
    <last_update_submitted>August 23, 2023</last_update_submitted>
    <last_update_submitted_qc>August 23, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 24, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Principal Investigator</responsible_party_type>
      <investigator_affiliation>Çankırı Karatekin University</investigator_affiliation>
      <investigator_full_name>Furkan Özdemir</investigator_full_name>
      <investigator_title>Lecturer</investigator_title>
    </responsible_party>
    <keyword>Dyslipidemia</keyword>
    <keyword>Calisthenic Exercise</keyword>
    <keyword>Exercise Capacity</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Dyslipidemias</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>No</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT06008912
  org study id: KA-22027
  nct id: NCT06008912
  lead sponsor: 
  collaborator: 
  has dmc: No
  is fda regulated drug: No
  is fda regulated device: No
  Dyslipidemia is expressed as the serum concentration of lipid molecules with different
        structures outside the normal level. Deviation of serum lipid level from normal is accepted
        as the primary or most important factor in various cardiac and metabolic diseases, especially
        atherosclerosis. Dyslipidemia-related cardiovascular structure change is accepted as an
        important public health problem worldwide, and it is stated that the combined use of medical
        treatment, changes in diet and physical activity/structured exercise programs in the
        treatment of dyslipidemia is important in the success of treatment.
  Lipid profile disorders (especially high total blood cholesterol level) are a major problem
        worldwide, and accepted as a important public health problem. It has been reported that
        approximately one out of every three people worldwide has been exposed to dyslipidemia risk
        factors. Prevalence studies showed that lipid profile disorders vary between 6.9% and 43.6%
        worldwide. Today, ischemic heart and central nervous system diseases are the most important
        causes of mortality and morbidity in adult population, globally. Especially, it is accepted
        that lipid profile disorders are the leading risk factors causing ischemic heart diseases.
  
        Prevalence varies according to regions, lifestyle habits and individual factors, because of
        lipid profile disorders are caused by many different genetic and environmental factors. Apart
        from individual factors, there are other factors that lipid weight in diet, nutrient
        deficiencies which balancing lipid metabolism, physical activity level and inactivity, other
        comorbid diseases, and medical treatments change lipid metabolism in individuals and lead to
        deterioration in lipid profile. Especially lifestyle habits affect lipid metabolism most
        easily and they are the most easily modifiable factors.
  
        It is recommended to apply a multi-dimensional approach when treating lipid profile
        disorders. It is recommended that, to include diet counseling and exercise therapy in these
        approaches. Exercise therapy is especially recognized as an important treatment option for
        the control and treatment of obesity, hypertension, hyperglycemia and metabolic syndrome
        symptoms that may accompany dyslipidemia.
  
        It has been reported that aerobic exercise programs increase patients' quality of life and
        functionality which applied to dyslipidemia patients, but there is lack of information
        available in literature about the effects of calisthenic exercises in patients with
        dyslipidemia.
  allocation: Randomized
  intervention model: Parallel Assignment
  intervention model description: Experimental model of study consist from three arm.
  First Arm: Patients will take aerobic exercise training in 3 days per week, and 7 days per week calisthenic exercises for upper extremity, lower extremity and trunk, for 8 weeks.
  Second Arm: Patients will take aerobic exercise training in 3 days per week, for 8 weeks.
  Third Arm: Patients will take physical activity recommendations, and just screening after 8 weeks.
  primary purpose: Treatment
  masking: Double (Participant, Care Provider)
  masking description: Patients and his/her caregivers will allocate in study via computer based randomisation, and will not know about his/her and also other participants group in study.
  measure: Exercise Capacity
  time frame: Second Day
  description: Cardiopulmonary exercise capacity will assess as primary outcome measure, via cardiopulmonary exercise test (CPET).
  measure: Blood Lipids Concentration Assessment
  time frame: First Day
  description: Concentration of LDL-C, HDL-C, Total cholesterol (TC) and Triglyceride (TG) will assess in blood (in mg/dL units of measure) after 12 hours fasting.
  measure: Apolipoprotein A1 Concentration Assessment
  time frame: First Day
  description: Concentration of Apolipoprotein A1 will assess in blood (in g/dL units of measure) after 12 hours fasting.
  measure: Blood Sugar Concentration Assessment
  time frame: First Day
  description: Concentration of fasting blood sugar (in mmol/L units of measure) and rate of HbA1c (in % units of measure) will assess in blood after 12 hours fasting.
  measure: C-reactive Protein Concentration Assessment
  time frame: First Day
  description: Concentration of C-reactive protein (in mg/dL units of measure) will assess in blood after 12 hours fasting.
  measure: Sit-to-Stand Test
  time frame: First Day
  description: A one-minute sit-to-stand test will be applied to the patients. One standing position followed by sitting will count as one cycle. Patients' total cycles within 60 seconds will be counted as test score (in cycle/minute units of measure)
  measure: Timed Up-and-Go Test
  time frame: First Day
  description: Timed up-and-go test will be applied to the patients. Patients will be asked to get up from the chair, walk the 3-meter distance, return and sit back in the chair, as quickly as possible. The total time that patients complete the test and sit on the chair again will be recorded as the test score (in second/lap units of measure).
  measure: Peripheral Muscle Strength Assessment
  time frame: First Day
  description: The muscle strength of the shoulder abductor and knee extensor muscles on the dominant and non-dominant sides of the patients will be evaluated with a portable dynamometer. During the evaluations, the patients will be asked to try to resist the force to be applied in the opposite direction of the relevant muscle's function with isometric muscle contraction. The force released during the test will be measured and the highest score (in newton [N] units of measure) will be recorded for each muscle within 3 tests.
  measure: Hand-Grip Strength Assessment
  time frame: First Day
  description: The hand grip strength of the patients will be measured with a portable hand dynamometer. The patients will be asked to grasp the dynamometer with their fingers on the dominant and non-dominant side and squeeze it most strongly. The highest score (in kilogram force [KgF] units of measure) of 3 measurements on both sides will be recorded.
  measure: Flexibility Assessment
  time frame: First Day
  description: Flexibility of patients will be evaluated with sit-and-reach test. Patients will be asked to stretch their hands on a bench with a measuring ruler while in a long sitting position with the ankle angled at 90 degrees and the knee fully extended. How many centimeters ahead or behind the toes of the patient's fingertips will be measured.
  measure: Quality of Life Assessment
  time frame: Second Day
  description: Quality of life will assess via Short Form-36 Quality of Life Questionnaire. The questionnaire consist from 36 questions and total score ranges between 0 to 100 point. Higher scores shows better quality of life.
  arm group label: Calisthenic + Aerobic Exercise Group
  arm group type: Experimental
  description: Patients will take aerobic exercise training in 3 days per week, and 7 days per week calisthenic exercises for upper extremity, lower extremity and trunk, for 8 weeks.
  arm group label: Aerobic Exercise Group
  arm group type: Active Comparator
  description: Patients will take aerobic exercise training in 3 days per week, for 8 weeks.
  arm group label: Control Group
  arm group type: No Intervention
  description: Patients will take physical activity recommendations, and just screening after 8 weeks.
  intervention type: Other
  intervention name: Calisthenic Exercises
  description: Exercises for upper extremity, lower extremity and trunk which applying just patient's own body weight via using body mechanics. There is no need for any tools for exercises.
  arm group label: Calisthenic + Aerobic Exercise Group
  intervention type: Other
  intervention name: Aerobic Exercises
  description: Exercises which loading cardiovascular, respiratory and muscular system at the same time. Treadmill training will apply in the study.
  arm group label: Aerobic Exercise Group
  arm group label: Calisthenic + Aerobic Exercise Group
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: 65 Years
  healthy volunteers: No
  last name: Naciye Vardar-Yağlı, Prof. Dr.
  phone: +90-546-237-1990
  email: naciyevardar@yahoo.com
  facility: 
  country: Turkey
  citation: GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016 Oct 8;388(10053):1659-1724. doi: 10.1016/S0140-6736(16)31679-8. Erratum In: Lancet. 2017 Jan 7;389(10064):e1.
  PMID: 27733284
  citation: Rivas-Gomez B, Almeda-Valdes P, Tussie-Luna MT, Aguilar-Salinas CA. DYSLIPIDEMIA IN MEXICO, A CALL FOR ACTION. Rev Invest Clin. 2018;70(5):211-216. doi: 10.24875/RIC.18002573.
  PMID: 30307444
  citation: Pan L, Yang Z, Wu Y, Yin RX, Liao Y, Wang J, Gao B, Zhang L; China National Survey of Chronic Kidney Disease Working Group. The prevalence, awareness, treatment and control of dyslipidemia among adults in China. Atherosclerosis. 2016 May;248:2-9. doi: 10.1016/j.atherosclerosis.2016.02.006. Epub 2016 Feb 27.
  PMID: 26978581
  citation: Zhang M, Deng Q, Wang L, Huang Z, Zhou M, Li Y, Zhao Z, Zhang Y, Wang L. Prevalence of dyslipidemia and achievement of low-density lipoprotein cholesterol targets in Chinese adults: A nationally representative survey of 163,641 adults. Int J Cardiol. 2018 Jun 1;260:196-203. doi: 10.1016/j.ijcard.2017.12.069. Erratum In: Int J Cardiol. 2018 May 12;:
  PMID: 29622441
  citation: Yang F, Ma Q, Ma B, Jing W, Liu J, Guo M, Li J, Wang Z, Liu M. Dyslipidemia prevalence and trends among adult mental disorder inpatients in Beijing, 2005-2018: A longitudinal observational study. Asian J Psychiatr. 2021 Mar;57:102583. doi: 10.1016/j.ajp.2021.102583. Epub 2021 Feb 5.
  PMID: 33581368
  citation: GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct 17;396(10258):1204-1222. doi: 10.1016/S0140-6736(20)30925-9. Erratum In: Lancet. 2020 Nov 14;396(10262):1562.
  PMID: 33069326
  citation: Tietge UJ. Hyperlipidemia and cardiovascular disease: inflammation, dyslipidemia, and atherosclerosis. Curr Opin Lipidol. 2014 Feb;25(1):94-5. doi: 10.1097/MOL.0000000000000051. No abstract available.
  PMID: 24398450
  citation: Villarreal-Molina MT, Aguilar-Salinas CA, Rodriguez-Cruz M, Riano D, Villalobos-Comparan M, Coral-Vazquez R, Menjivar M, Yescas-Gomez P, Konigsoerg-Fainstein M, Romero-Hidalgo S, Tusie-Luna MT, Canizales-Quinteros S; Metabolic Study Group. The ATP-binding cassette transporter A1 R230C variant affects HDL cholesterol levels and BMI in the Mexican population: association with obesity and obesity-related comorbidities. Diabetes. 2007 Jul;56(7):1881-7. doi: 10.2337/db06-0905. Epub 2007 Feb 7.
  PMID: 17287470
  citation: Villarreal-Molina MT, Flores-Dorantes MT, Arellano-Campos O, Villalobos-Comparan M, Rodriguez-Cruz M, Miliar-Garcia A, Huertas-Vazquez A, Menjivar M, Romero-Hidalgo S, Wacher NH, Tusie-Luna MT, Cruz M, Aguilar-Salinas CA, Canizales-Quinteros S; Metabolic Study Group. Association of the ATP-binding cassette transporter A1 R230C variant with early-onset type 2 diabetes in a Mexican population. Diabetes. 2008 Feb;57(2):509-13. doi: 10.2337/db07-0484. Epub 2007 Nov 14.
  PMID: 18003760
  citation: De Sousa SM Dr, Norman RJ Prof. Metabolic syndrome, diet and exercise. Best Pract Res Clin Obstet Gynaecol. 2016 Nov;37:140-151. doi: 10.1016/j.bpobgyn.2016.01.006. Epub 2016 Feb 10.
  PMID: 26972165
  citation: Wang Y, Xu D. Effects of aerobic exercise on lipids and lipoproteins. Lipids Health Dis. 2017 Jul 5;16(1):132. doi: 10.1186/s12944-017-0515-5.
  PMID: 28679436
  citation: Miles L. Physical activity and health. Nutr Bull [Internet]. 2007 Dec;32(4):314-63. Available from: http://doi.wiley.com/10.1111/j.1467-3010.2007.00668.x
  citation: Strunk RC, Mrazek DA, Fukuhara JT, Masterson J, Ludwick SK, LaBrecque JF. Cardiovascular fitness in children with asthma correlates with psychologic functioning of the child. Pediatrics. 1989 Sep;84(3):460-4.
  PMID: 2771549
  citation: Carson KV, Chandratilleke MG, Picot J, Brinn MP, Esterman AJ, Smith BJ. Physical training for asthma. Cochrane Database Syst Rev. 2013 Sep 30;(9):CD001116. doi: 10.1002/14651858.CD001116.pub4.
  PMID: 24085631
  citation: Eime RM, Young JA, Harvey JT, Charity MJ, Payne WR. A systematic review of the psychological and social benefits of participation in sport for children and adolescents: informing development of a conceptual model of health through sport. Int J Behav Nutr Phys Act. 2013 Aug 15;10:98. doi: 10.1186/1479-5868-10-98.
  PMID: 23945179
  responsible party type: Principal Investigator
  investigator affiliation: Çankırı Karatekin University
  investigator full name: Furkan Özdemir
  investigator title: Lecturer
  mesh term: Dyslipidemias
  sharing ipd: No